Presage Biosciences, Inc.’s Post

Today we filed our fiscal year end financials with SEDAR and shared a summary of key 2023 accomplishments, including positive T1D clinical results, along with select 2024 milestones (it's going to be an exciting year for Sernova!): 📈 Additional data from Cohort 2 of the ongoing U.S. Phase 1/2 clinical trial, which is evaluating its enhanced 10-channel Cell Pouch in patients with T1D, are expected beginning in Q1. ⚕️Additional preclinical data to support an IND application to evaluate the Company’s autograft thyroid cells in patients suffering from thyroid disease, with no immunosuppressive regimen required. 🤝 Potential engagement with additional life sciences focused companies, academic institutions and external parties through partnership and collaboration opportunities, which could be announced over the course of 2024. 💰 Additional funding to support growth through strategic alliances, credit facilities and/or institutional equity financings with the goal of maximizing shareholder value. #T1D #IND #CellTherapy #Biotechnology

The transition from preclinical experiments to first-in-human clinical trials signifies a significant milestone in the development of any new drug candidate. A thorough understanding of the molecule’s characteristics and behavior in humans, including dose-response relationship, safety signals, and key PKPD parameters, facilitated by the right study design and accurate execution, is crucial for informed decision-making. During this webinar in association with American Society for Clinical Pharmacology & Therapeutics we will discuss best practices in FIH and hADME studies including cohort planning and dose selection, options for running a hADME study, and the progression into early patient studies. Register here: https://ow.ly/6ngv50Ruq0Z

Fantastic webinar for those planning future first-in-human (FIH) and human ADME studies!

Come join us for this webinar where we discuss strategies and considerations for FIH trials!!

Here is an example of the sort of ion channel drug discovery consultancy work that I enjoy doing - writing about the scientific and industrial applications of automated patch clamp (APC)...

Wild progress by Insilico Medicine: The 10th AI-Driven IND Clearance! As an early investor in Insilico Medicine, it’s truly inspiring to see the company hit yet another major milestone—FDA IND clearance for ISM5939, its 10th AI-enabled drug candidate. Watching Insilico evolve from a bold idea into a clinical-stage powerhouse using generative AI to boost drug discovery has been an incredible journey. This time, ISM5939 is leading the charge as a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. Insilico’s AI platform, PharmaAI developed this novel compound in just three months—yes, three months—from project initiation to lead optimization. That’s not just speed; it’s a new level of efficiency in drug discovery in my opinion. A hard one to match. But let me remind you of a broader story. Since 2021, Insilico has nominated 20 preclinical candidates and secured 10 IND clearances (!), all powered by its proprietary AI platforms like Chemistry42 And let’s not forget ISM001_055, their flagship molecule, which recently delivered positive results in a Phase IIa clinical trial. Insilico isn’t just proving the concept of AI-driven drug discovery—it’s building a pipeline, advancing programs, and showing the world what the future of medicine looks like. Kudos to the brilliant team at Insilico for continuing to push boundaries and make AI-driven therapeutics a reality (and investors happy!). I think this 10th anniversary is a good new year present for InSilico team, what do you think Alex Zhavoronkov and Alex Aliper? #generativeai #genai #drugdiscovery

The transition from preclinical experiments to first-in-human clinical trials signifies a significant milestone in the development of any new drug candidate. A thorough understanding of the molecule’s characteristics and behavior in humans, including dose-response relationship, safety signals, and key PKPD parameters, facilitated by the right study design and accurate execution, is crucial for informed decision-making. During this webinar in association with American Society for Clinical Pharmacology & Therapeutics we will discuss best practices in FIH and hADME studies including cohort planning and dose selection, options for running a hADME study, and the progression into early patient studies. Register here: https://ow.ly/6ngv50Ruq0Z

The 12th Alzheimer’s & Parkinson’s Drug Development Summit unites 150+ drug developers from across drug discovery, translation, biomarker R&D, clinical and commercial development to accelerate a new era of neurodegenerative therapeutics. Attend this April to learn more about the latest innovations in 3D cell cultures of hIPSC and microglia prion pathology models, recent unpublished preclinical data from UCB & Janssen, AI & ML driven approaches for target ID and validation, while learning from the latest progress in Alzheimer’s clinical development. https://bit.ly/3TWPcox

Enveric Biosciences, Inc. (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile.

Insilico Medicine is spearheading ML-driven drug development, with its first drug for treating pulmonary fibrosis already in clinical trials. AI/ML has garnered a lot of, well justified, cynicism, but this paper by Insilico in Nature Biotech, outlining their in silico-to-clinic pipeline helps demystify the process. https://lnkd.in/eZT-qXjJ